Abrocitinib
Abrocitinib is a prescription medication classified as a Janus kinase 1 (JAK1) inhibitor used to treat moderate-to-severe atopic dermatitis in adults. It works by selectively blocking the JAK1 enzyme, which plays a key role in the inflammatory processes underlying certain skin conditions.
Abrocitinib is a JAK1-selective inhibitor used to treat moderate-to-severe atopic dermatitis in adults.
This medication carries a boxed (black box) warning — the strongest type of FDA warning. Review the full prescribing information before use.
Key facts at a glance
- ATC
- D11AH08
- RxNorm
- 2591476
- Generic
- Abrocitinib
- Class
- atc-d11
- Brands
- Cibinqo
- Availability
- rx
- Lactation
- unknown
- Routes
- oral
- Forms
- tablet
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Dosage and administration
- Usual dose
- 500mg twice daily
- Maximum
- consult physician
- Frequency
- every 12 hours
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 250mg twice daily
- Maximum
- consult physician
- Frequency
- every 12 hours
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 400mg daily
- Maximum
- consult physician
- Frequency
- once daily
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
Overdose information
Special Populations
9 groupspregnancy
first trimesteravoid if possible
avoid use during pregnancy unless benefits outweigh risks; women of childbearing potential should use effective contraception during treatment
regular fetal monitoring
Use of this medication in this population requires careful consideration of risks and benefits.
pregnancy
second and third trimesteravoid if possible
avoid use during pregnancy; discontinue therapy if pregnancy occurs
regular fetal monitoring and ultrasound assessments
Use of this medication in this population requires careful consideration of risks and benefits.
lactation
n adiscontinue breastfeeding
do not use during breastfeeding; a decision must be made whether to discontinue breastfeeding or discontinue abrocitinib therapy
monitor infant for signs of infection
Use of this medication in this population requires careful consideration of risks and benefits.
pediatric_age
under 18 yearsnot recommended
safety and efficacy have not been established in patients under 18 years of age; avoid use in pediatric population
n/a - not approved for this population
Use of this medication in this population requires careful consideration of risks and benefits.
geriatric
age 65 and olderno specific dose adjustment required
use with caution; start at lower end of dosing range; increased risk of infections and malignancy in elderly patients
regular monitoring for signs of infection, malignancy, and cardiovascular events
Use with caution and monitor for adverse effects.
renal_impairment
moderate crcl 30 60reduce dose to 100mg once daily
reduce starting dose to 100mg once daily; monitor renal function regularly
regular monitoring of renal function; adjust dose based on tolerability
Use with caution and monitor for adverse effects.
renal_impairment
severe crcl less than 30reduce dose to 50mg once daily
reduce dose to 50mg once daily; use with caution; not recommended for end-stage renal disease
close monitoring of renal function; watch for adverse effects
Use with caution and monitor for adverse effects.
hepatic_impairment
moderate child pugh breduce dose to 100mg once daily
reduce dose to 100mg once daily; monitor liver function tests
regular monitoring of liver function tests
Use with caution and monitor for adverse effects.
hepatic_impairment
severe child pugh cavoid use
do not use in patients with severe hepatic impairment
n/a - contraindicated
Use of this medication in this population requires careful consideration of risks and benefits.
Statistics and clinical data
Drug class
Janus kinase 1 selective inhibitor
FDA approval year
FDA approval for atopic dermatitis
Primary indication
Therapeutic indication
Brand name
Commercial brand name
Abrocitinib is indicated for the treatment of moderate-to-severe atopic dermatitis (eczema) in adult patients who have not responded adequately to other treatment options.
Abrocitinib reversibly inhibits the Janus kinase 1 (JAK1) enzyme by blocking the adenosine triphosphate (ATP) binding site. It demonstrates high selectivity for JAK1 over JAK2 (28-fold), JAK3 (>340-fold), and tyrosine kinase 2 (TYK2), which helps target the inflammatory pathways involved in atopic dermatitis.
As a JAK inhibitor, abrocitinib may increase the risk of serious infections, malignancy, and cardiovascular events. It is taken orally and should be used under the supervision of a healthcare provider experienced in treating atopic dermatitis. Patients should discuss their complete medical history, including current medications, before starting treatment.
Contraindications
Conditions and patient states where this medication should be avoided or used with caution.
Do not use (1)
Known allergy to this medication or its components
Use caution (1)
Consult healthcare provider for benefits vs risks assessment
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy